Oxford BioTherapeutics Initiates U.S. Phase I Clinical Trial

Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid … Continued

Calculus invests in Wonderhood Studios

Calculus Capital is delighted to announce its investment in Wonderhood Studios, the creative business founded by former Channel 4 CEO David Abraham and senior partners from the TV production and advertising sectors. Wonderhood is introducing a new hybrid model as … Continued

Genedrive: Antibiotic Induced Hearing Loss Assay receives CE marking

genedrive’s genetic screening test could prevent thousands of infants from needlessly going deaf. genedrive plc, the near patient molecular diagnostics company, announced that its Antibiotic Induced Hearing Loss test, the Genedrive® MT-RNR1 ID kit, has obtained CE marking. The Genedrive® … Continued

Sherlock Bioscience and Mologic enter partnership

Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings. Mologic said it will invest a part of an … Continued